Introduction
============

Hepatitis B virus (HBV) infection is an important public health problem worldwide. It has been estimated that as much as 40% of men and 15% of women with perinatally acquired chronic HBV infection will die of liver cirrhosis or hepatocellular carcinoma [@B1].

HBV is a small enveloped hepatotropic DNA virus, with a \~3.2 kb long, partially double-stranded relaxed circular DNA (rcDNA) genome, which is reversely transcribed from the pregenomic RNA (pgRNA). Upon infection, rcDNA is transported into nucleus where it is converted into covalently closed circular DNA (cccDNA). As a template for HBV replication, cccDNA is responsible for all viral transcripts including pgRNA [@B2], [@B3]. Chronic HBV infection is characterized by the persistence of HBV cccDNA in the nucleus of the infected hepatocyte. Unfortunately, none of the currently used antiviral agent could efficiently eradicate cccDNA, so it is still difficult to achieve clinical cure of chronic hepatitis B (CHB) [@B4]-[@B6]. Besides, we and other groups have proved that the encapsidated HBV pgRNAs can be released as extracellular HBV pgRNA virions, which may be associated with persistence of viral infection and rebound [@B7], [@B8]. As we know, HBV pgRNA is directly transcribed from cccDNA. Therefore, a new strategy aimed to eradicate cccDNA is of clinical significance.

Currently, genome editing technologies bring light to the antiviral therapy of HBV, including zinc finger nucleases (ZFNs) [@B9], [@B10], transcription activator-like effector nucleases (TALENs) [@B11], [@B12], and the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated (Cas) system [@B13]-[@B16]. Compared with ZFNs and TALENs, CRISPR/Cas system is superior for its easier genome editing [@B17]-[@B19]. Type II CRISPR/Cas system consisting of DNA endonuclease Cas9, CRISPR RNAs (crRNAs) and trans-activating crRNAs (tracrRNAs) is the simplest CRISPR/Cas system, particularly after fusing the crRNA and tracrRNA into a single chimeric guide RNA (gRNA) [@B20], [@B21]. The specific gRNA directs Cas9 to the target DNA sequence called the protospacer on the target DNA next to the protospacer adjacent motif (PAM) for site-specific cleavage [@B22], [@B23]. For anti-HBV therapy, we have proved that dual gRNAs guided CRISPR/Cas9 system showed a synergistic effect in suppressing HBV replication [@B24]. Besides, a lot of miRNAs have been proved to be involved in the control of HBV replication by directly targeting to HBV mRNAs or by indirectly regulating cellular transcription factors [@B25]. Recently, TALENs or CSRISPR/Cas9 nucleases were used to site-specifically integrate an anti-hepatitis C virus (HCV) shmiRNA into an engineered genomic miRNA (miR-122/*hcr*) locus in hepatoma cells, and successfully impair HCV replication, which was an original combination of DNA engineering and RNAi expression technologies [@B26].

There are several approaches to enable simultaneous expression of two gRNAs, including the crRNA array [@B27], U6-gRNA cassette in tandem [@B28], dimeric RNA-guided FokI nucleases (RFNs) [@B29] and Cas6/Csy4-based RNA processing strategies [@B29], [@B30]. Here, we developed a powerful approach in inhibiting HBV replication, which combined the CRISPR/Cas9 and RNAi approaches together. In this approach, a gRNA-microRNA (miRNA)-gRNA ternary cassette was designed, which used the endogenous nuclear RNaseIII enzyme Drosha/DGCR8 to process pri-miRNA and produce a pre-miRNA and two HBV-specific gRNAs. To increase the antiviral efficiency, the anti-HBV pri-miR-31 mimic was used to produce miR-HBV, which had a similar structure to that of naturally occurring pri-miR-31 [@B31], [@B32]. Moreover, we evaluated the potential value of using the gRNA-miR-HBV-gRNA ternary cassette to clear HBV cccDNA.

Materials and Methods
=====================

Plasmids
--------

The gRNA/Cas9 dual expression vector pSpCas9 (BB)-2A-GFP (PX458) was obtained from Addgene (Addgene, Cambridge, MA). The pSpCas9(BB)-2A-GFP-XhoI/HindIII (PX458M) plasmid was constructed by inserting XhoI and HindIII restriction endonucleases cutting sites into PX458 plasmid, using QuikChange site-directed mutagenesis method (Agilent technologies, Santa Clara, CA). The primers were 5\'- TGGCACCGAGTCGGTGCCTCGAGTCCAAGCTTAGGCTAGTCCGTTTTTAGCGC-3\' (Forward) and 5\'- GCGCTAAAAACGGACTAGCCTAAGCTTGGACTCGAGGCACCGACTCGGTGCCA-3\' (Reverse). The pSpgRNA3-Pri-miR31(51+51)/miR-HBV-gRNA2-Cas9(BB)-2A-GFP (3-H51-2) vector was constructed by ligating the annealed oligo-nucleotides of gRNA3 into the PX458M plasmid digested with Bbsl enzyme, then the plasmid was digested with XhoI and HindIII enzymes (New England Biolabs, Ipswich, MA), and ligated with synthesized gene fragment pri-miR-31(51+51)/miR-HBV-gRNA2. The gRNA3-H22-gRNA2 (3-H22-2), gRNA3-H30-gRNA2 (3-H30-2), gRNA3-H38-gRNA2 (3-H38-2) and gRNA3-mutant miR-HBV (38 bp flanking sequence)-gRNA2 (3-M38-2) plasmids were constructed by ligating the annealed oligo-nucleotides ([Supplementary Table](#SM1){ref-type="supplementary-material"} S1) or synthesized gene fragment ([Supplementary Table](#SM1){ref-type="supplementary-material"} S2) into the 3-H51-2 plasmid digested with XhoI and HindIII. The pSpgRNA3-gRNA2-Cas9(BB)-2A-GFP (gRNA3-gRNA2) plasmid was constructed by ligating the synthesized gene fragment ([Supplementary Table](#SM1){ref-type="supplementary-material"} S2) into the PX458M plasmid digested with XhoI and HindIII. The pGL3-HBV (1575-1604) plasmid was constructed by ligating the annealed oligo-nucleotides containing the miR-HBV target sequence \[nt 1575-1595: CCGTGTGCACTTCGCTTCACC (Genebank accession AB014381)\] and the pGL3-control plasmid digested with XbaI enzyme. The oligo-nucleotides were 5\'- CTAGCCGTGTGCACTTCGCTTCACCTCTGCACGT-3\' (Top) and 5\'- CTAGACGTGCAGAGGTGAAGCGAAGTGCACACGG-3\' (Bottom). The expression plasmids of PX458-miR-HBV and PX458-mutant miR-HBV was constructed by PCR from the expression plasmids of 3-H38-2 and 3-M38-2 ternary cassette respectively, and subsequently ligated PCR products and PX458M plasmid digested with Bbsl and HindIII. The sequences of oligo-nucleotides and synthesized gene fragment for constructing the HBV-specific double gRNAs/Cas9 dual expression vectors were listed in Table [S2](#SM1){ref-type="supplementary-material"} and S3. The 1.2×HBV construct (pBB4.5-HBV1.2, genotype C) was constructed using a 1.2-fold length genome of genotype C HBV DNA sequence, based on pBB4.5-HBV1.3 (genotype D, G1896A mutation) which was kindly provided by professor Locarnini SA from the Victorian Infectious Diseases Reference Laboratory, Australia [@B33]. The HBV-expression vectors pGEM-HBV1.3A (genotype A) and pGEM-HBV1.3B (genotype B) were kindly provided by Professor Ningshao Xia from School of Public Health, Xiamen University, China.

Cell transfection
-----------------

HepG2-NTCP-tet cells, in which the expression of sodium taurocholate cotransporting polypeptide (NTCP) gene was tetracycline inducible, was kindly provided by State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University. Xiamen, Fujian, China. HepG2-NTCP-tet cells, human liver cancer cell lines HuH7 and HepAD38 (stable expression of HBV) were maintained in Dulbecco modified Eagle medium supplemented with 10% fetal bovine serum (Gibco, Carlsbad, CA). HuH7 and HepAD38 cells were seeded in a 12-well plate at 2×10^5^cells/well. HuH7 cells were co-transfected with HBV expression vectors (HBV of genotype A, B or C) and HBV-specific gRNA/Cas9 dual expression vector (pSpCas9(BB)-2A-GFP) by lipofectamain 2000 (Life technologies, Carlsbad, CA). HepAD38 cells and HepG2-NTCP-tet cells were transfected with HBV specific gRNA/Cas9 dual expression vector by lipofectamain 3000 (Life technologies).

Dual luciferase reporter assay
------------------------------

HuH7 cells were seeded in a 12-well plate at 2×10^5^ cells/well and allowed to grow for 16-24 h, then transiently co-transfected with the pGL3-HBV (1575-1604) or pGL3-control, PRL-TK and gRNA3-H22-gRNA2 or gRNA3-H30-gRNA2 or gRNA3-H38-gRNA2 or gRNA3-H51-gRNA2 plasmids. The luciferase activity in each well was quantified using a dual luciferase reporter kit (Promega, Madison, WI) at 36 hours post transfection, and was detected by EnSpire multimode plate reader (PerlinElmer, Waltham, MA) following the manufacturer\'s protocol.

RNA extraction, PolyA tailing, Reverse transcription and PCR amplification
--------------------------------------------------------------------------

Small RNA was extracted by mirVana^TM^ miRNA Isolation Kit (Life technologies), and the RNA was added polyA using Poly(A) Tailing Kit (Life technologies) in accordance with manufacturer\'s instructions. The reverse transcription was performed using Transcriptor First Strand cDNA Synthesis Kit (Roche, Basel, Switzerland) in accordance with manufacturer\'s instructions. The reverse transcription primers RT-miR-HBV (5\'-ACCACGCTATCGCTACTCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCGTGTGC-3\'), RT-mutant miR-HBV (5\'- ACCACGCTATCGCTACTCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTAGCTATGC-3\') and RT-gRNA3 (5\'-ACCACGCTATCGCTACTCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTCCTCTCCAG-3\') were used for the detection of mature miR-HBV, mutant miR-HBV and gRNA3 carrying the flanking sequence of anti-HBV pri-miR31 mimic separated by the endogenous Drosha/DGCR8 system. The reverse transcription primer RT-random (5\'-ACCACGCTATCGCTACTCACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT-3\') was used for the detection of gRNA2 and 5S rRNA. PCR or qPCR amplification was performed using the following primers to detect the small RNAs. Primers miR-HBVF: 5\'-GGTGAAGCGAAGTGCACACG-3\', miR-HBVmF: 5\'-GGTGAAGCGAATGGCATAGC-3\', 5\'-CAAGCCTCCAAGCTGTGCCT-3\', 5\'-GGTTGCGTCAGCAAACACT-3\' and AnchoredR: 5\'-ACCACGCTATCGCTACTCAC-3\' were used to detect mature miR-HBV, mutant miR-HBV, gRNA3 and gRNA2, respectively. Primers 5SF: 5\'-5SF: CCATACCACCCTGAACGC-3\' and 5SR: 5\'-AGCCTACAGCACCCGGTAT-3\' were used to detect 5S rRNA.

HBV infection
-------------

HBV infection of HepG2-NTCP-tet cells was conducted as previously described [@B34]. Briefly, HepG2-NTCP-tet cells which were maintained in DMEM medium containing 2μg/ml Doxycycline (Merk, Kenilworth, NJ) for 4 days were seeded in a 24-well plate (2×10^5^cells/well), and were inoculated with 2×10^7^ copies of genome equivalent HBV in the presence of 4% PEG 8000 for 20 hr. HepG2-NTCP cells cells were then washed with PBS six times and maintained in fresh DMEM medium.

Detection of HBsAg and HBeAg
----------------------------

Cell pellet and culture supernatant were harvested at 72 hours post transfection, and the levels of HBsAg and HBeAg were detected by a time-resolved fluoroimmunoassay (TRFIA) according to manufacturer\'s instructions (PerkinElmer). In brief, culture supernatant (100 μl) was added into a microtiter plate coated with anti-HBs or anti-HBe and shaked for 40 min in room temperature, then washed for 4 times. Europium-labeled anti-HBsAg or anti-HBeAg was diluted 1:50 by HBsAg or HBeAg dilution buffer and added at 100 μl per well, shaked for 40 min in room temperature, then washed for 6 times. At last, after incubation with enhancement solution (100 μl) for 5 min, the plates were read using Anytest reader (PerkinElmer).

Detection of HBV DNA fragments cleaved by dual gRNAs
----------------------------------------------------

DNA was extracted from cells using QIAGEN DNA mini kit (Qiagen, Hilden, Germany) in accordance with the manufacturer\'s instruction. Specific primers listed below were used to PCR amplify the cleaved HBV DNA fragments. HBV1856F: 5\'-CCTACTGTTCAAGCCTCCAAGC-3\'; HBV434R: 5\'-AGAAGATGAGGCATAGCAGC-3\'; HBV321F: 5\'-CAACCTCCAATCACTCACCAAC-3\'; HBV2006R: 5\'-CTAGGAGTTCCGCAGTATGGAT-3\'. HBV1856F and HBV434R were used for detection the fragment cleaved by dual gRNAs of gRNA1+4; HBV321F and HBV2006R were used for detection the fragment cleaved by dual gRNAs of gRNA2+3, respectively.

PCR reaction mixture (20 μl) contained 2×Taq mix 10 μl, forward primer (10 μM) 1 μl, reverse primer (10 μM) 1 μl, DNA template (200 ng/μl) 1 μl and double distilled water 7 μl. The reaction mixture was denatured at 95°C for 5 min, followed by 35 cycles at 95°C for 30 s, 60°C for 30 s, 72°C for 1 min, and at last 72°C for 5 min. Agarose gel (1.5%) was used for separation of DNA fragments with different length. The DNA fragment of expected length was sequenced.

Southern Blot
-------------

Total cellular DNA was extracted from the transfected HuH7 cells (3 × 10^6^ cells each group) using QIAGEN DNA mini kit (Qiagen). DNA samples were resolved on a 1.0% agarose gel, transferred to a nylon membrane (Bio-Rad, Hercules, CA, USA), and hybridized with a digoxin-labeled DNA fragment covering the whole HBV genome. The probe was amplified from pGEM-HBV1.3A and pGEM-HBV1.3B plasmid, and labeled with PCR DIG Probe Synthesis Kit (Roche, Mannheim, Germany), respectively. The primers were 5\'-TTTGCCTTCTGACTTCTTTC-3\' (1954-1973 nt) and 5\'-CCAAATTCTTTATAMGGGTC-3\' (1929-1910 nt).

Western Blot
------------

Western Blot analysis was performed as previously described [@B7]. Briefly, the protein lysates (total 60 μg) dissolved in 1×laemmli buffer (with 5% 2-mercaptoethanol), boiled for 10 min and resolved on 4-12% gradient SDS-PAGE gel (BioRad). Subsequently, the proteins were transferred to a nitrocellulose membrane and incubated with mouse anti-core protein antibody (1μg/mL, a gift from State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University. Xiamen, Fujian, China) and rabbit anti-β-actin antibody (1μg/mL, Santa Cruz Biotech, Dallas, TX, USA) overnight at 4℃. Reactive proteins were developed with anti-mouse and anti-rabbit antibodies conjugated to horseradish peroxidase (Zhongshan Golden Bridge, Beijing, China), and visualized using SuperSignal™ West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer\'s protocol.

Detection of HBV cccDNA
-----------------------

Two gRNA/Cas9 dual expression vectors were co-transfected into HepAD38 cells at least 7 days after tetracycline removed, and the cells were harvested at 72 hours post of transfection. The DNA was extracted from cells using QIAGEN DNA mini kit (Qiagen) in accordance with the manufacturer\'s instruction. To obtain cccDNA, KCl precipitation was used to isolate HBV cccDNA [@B6], [@B35], and plasmid-safe^TM^ ATP-dependent DNase (PSAD) (Epicentre, Madison, WI) were used to enhance the specificity of cccDNA detection, for it can digest the integrated linear HBV DNA, the residue HBV rcDNA, double-strand linear (DSL) and single-strand (SS) DNA [@B36], [@B37]. Afterwards, rolling Circle Amplification (RCA) was conducted to selectively amplify cccDNA. Finally, PCR was performed using RCA products as template, and using cccDNA specific primers which target the gap region of HBV genome.

Hydrodynamic injection (HDI)
----------------------------

The hydrodynamic injection was performed as previously described [@B38]. Briefly, 8 µg 1.2×HBV expression and 24µg control (vector), 3-2 binary or 3-H38-2 ternary cassette expression plasmids were injected into the tail vein of C57BL/6 mice (5-7 weeks old) in 2 ml PBS to each mouse (almost equivalent to 8% of the mouse body weight) within 5 seconds. There were 8 mice in each group. Sera were collected at 3, 5 and 7 days post-injection. Two mice were sacrificed at 72 hours post-injection, and the liver was removed. One part of liver was frozen in liquid nitrogen and grinded for DNA extraction, the other part of liver was fixed for immunohistochemistry analysis. The HBsAg levels in sera and HBV DNA detection were performed as above description. All mouse care and experiments were carried out according to the guidelines established by the Institutional Animal Care and Use Committee at the Peking University Health Science Center. All mouse experiments were approved by the Institutional Animal Care and Use Committee at the Peking University Health Science Center.

Immunohistochemistry (IHC)
--------------------------

The mice were sacrificed at 72 hours post-injection, and the liver was removed and fixed in formalin (3.7% Formaldehyde in PBS) for immunohistochemistry analysis, HBcAg was detected by immunohistochemical staining by rabbit anti-HBc (DAKO, Carpinteria, CA; Biomeda, Foster City, CA) and MaxVision TM HRP-Polymer anti-Rabbit IHC Kit (Maixin, Fuzhou, China).

Statistical analysis
--------------------

For statistical analyses, Mann-Whitney U test and Kruskal-Wallis H (K) test were conducted using (SPSS Statistics 21.0). In all cases, a *P*value of less than 0.05 was considered significant.

Results
=======

Construction of HBV-specific gRNA-miR-HBV-gRNA ternary cassette
---------------------------------------------------------------

Structure of the ternary cassette producing two HBV-specific gRNAs and a miR-HBV is depicted schematically in Figure [1](#F1){ref-type="fig"}A. This gRNA-miR-HBV-gRNA ternary cassette should express a long RNA transcript containing two HBV-specific gRNAs and an anti-HBV pri-miR-31 mimic under the control of a U6 RNA polymerase (Pol) III promoter. Subsequently, the anti-HBV pri-miR-31 mimic would be processed by the endogenous Drosha/DGCR8, thus a pre-miR-HBV and two HBV-specific gRNAs containing part of pri-miR-31 flanking sequence would be ultimately separated (Figure [1](#F1){ref-type="fig"}A). To design the HBV-specific gRNA, the target sites of HBV-specific gRNAs were searched at different regions of HBV genome, which were conserved among genotypes A-D (Figure [1](#F1){ref-type="fig"}B). The target sequences of HBV-specific gRNAs were shown in [Supplementary Table](#SM1){ref-type="supplementary-material"} S3.

The anti-HBV pri-miR-31 mimic has a similar structure to that of naturally occurring pri-miR-31, which was designed by replacing the mature miR-31 with miR-HBV sequence predicted by the MFold algorithm [@B32]. The target site of miR-HBV was also shown in Figure [1](#F1){ref-type="fig"}B. The length of pri-miRNA backbones is considered as a variable affecting the recognition of Drosha/DGCR8 and the flanking sequences of gRNA may interfere with the gRNA-mediated cleavage of target sequences. Therefore, to optimize the anti-HBV efficiency of gRNA-miR-HBV-gRNA cassette, different lengths of anti-HBV pri-miR-31 mimics were designed (Figure [1](#F1){ref-type="fig"}C). The full DNA sequences of all gRNA-miR-HBV-gRNA cassettes were shown in [Supplementary Table](#SM1){ref-type="supplementary-material"} S4.

The gRNA-miR-HBV-gRNA ternary cassette can efficiently produce HBV-specific gRNAs and miR-HBV
---------------------------------------------------------------------------------------------

Based on the length of anti-HBV pri-miR-31 mimics, we constructed a series of gRNA3-miR-HBV-gRNA2 (3-Hn-2) cassettes including 3-H22-2, 3-H30-2, 3-H38-2 and 3-H51-2, which were inserted into pSpCas(BB)-2A-GFP (PX458) plasmid respectively. Two gRNA3-miR-HBV-gRNA2 cassettes (3-H38-2 and 3-H51-2) were chosen to confirm the expression of individual gRNAs and miR-HBV (Figure [2](#F2){ref-type="fig"}A). To specifically amplify the separated HBV-specific gRNA and miR-HBV, a polyA tailing method combined with anchoring random sequence through reverse transcription and PCR amplification was employed. Since gRNA2 was located at the 3\' end of gRNA3-miR-HBV-gRNA2 ternary cassette, both gRNA2 in the long gRNA3-miR-HBV-gRNA2 transcript and gRNA2 separated by endogenous Drosha/DGCR8 could be added polyA. Consequently, polyA-tailed gRNA2 could not specifically reflect the formation of separated gRNA2. Therefore, gRNA3 and miR-HBV were detected in this study. As shown in Figure [2](#F2){ref-type="fig"}B, HBV-specific gRNA3 and miR-HBV were successfully expressed and separated from 3-H38-2 and 3-H51-2 ternary cassettes. Moreover, these PCR products were purified and inserted into pEASY-Blunt Cloning vector, and the expression of mature miR-HBV and the polyA-tailed gRNA3 carrying different flanking sequences of anti-HBV pri-miR-31 mimics were further confirmed by the clone-based sequencing analyses (Figure [2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D).

The flanking sequence of anti-HBV pri-miR-31-mimic can influence the efficiency of ternary cassette in suppressing HBV replication
----------------------------------------------------------------------------------------------------------------------------------

To further demonstrate the functional miR-HBV was expressed from gRNA-miR-HBV-gRNA ternary cassette, the HBV specific sequence (1575-1604 nucleotides in HBV genome) containing the target sequence (1575-1595 nucleotides in HBV genome) of miR-HBV was inserted into the 3\'UTR region of luciferase gene in pGL3-control vector, and the production of functional miR-HBV was assessed by a dual luciferase assay. The results revealed that all gRNA3-miR-HBV-gRNA2 ternary cassettes with different lengths of anti-HBV pri-miR-31-mimic could efficiently suppress the activity of luciferase gene which carries the target sequence of miR-HBV at the 3\'UTR region, and the efficiency was increased along with the increase in the length of anti-HBV pri-miR-31 mimic (Figure [3](#F3){ref-type="fig"}A). Consistently, the level of mature miR-HBV expressed from gRNA3-miR-HBV-gRNA2 ternary cassette was also increased along with the increase in the length of anti-HBV pri-miR-31 mimic, and the longest anti-HBV pri-miR-31 mimic carrying 51 bp flanking sequences could produce the most mature miR-HBV in this study (Figure [3](#F3){ref-type="fig"}B).

To assess the antiviral efficiency of gRNA-miR-HBV-gRNA ternary cassette, the gRNA3-gRNA2 binary cassette (3-2) in which two gRNAs were transcribed from different U6 promoters was constructed (Figure [3](#F3){ref-type="fig"}C). As shown in Figure [3](#F3){ref-type="fig"}D, all of the gRNA3-miR-HBV-gRNA2 ternary cassettes exhibited higher efficiency in suppressing HBV replication than that of gRNA-gRNA binary cassette. Whereas, not the 3-H51-2 ternary cassette carrying the longest (51 bp) flanking sequence of anti-HBV pri-miR-31 mimic but the 3-H38-2 ternary cassette showed the highest efficiency in suppressing HBV replication.

The miR-HBV and two HBV-specific gRNAs in gRNA-miR-HBV-gRNA ternary cassette can get a synergistic effect in suppressing HBV replication
----------------------------------------------------------------------------------------------------------------------------------------

To explore the effect of miR-HBV and two HBV-specific gRNAs expressed from gRNA-miR-HBV-gRNA ternary cassette in suppressing HBV replication, the sequence of miR-HBV in 3-H38-2 ternary cassette was mutated to lose the recognition ability of its target sequence, which was named as gRNA3-miR-HBVm-gRNA2 (3-M38-2) ternary cassette (Figure [4](#F4){ref-type="fig"}A). Meanwhile, the mutant miR-HBV was confirmed to lose the ability in suppressing HBV replication, which could be used as a negative control of miR-HBV (Figure [4](#F4){ref-type="fig"}B). Besides, the vector control plasmid used in each experiment was pSpCas9 (BB)-2A-GFP (PX458) which expressed a nonsense gRNA (GGGTCTTCGAGAAGACCT). Thus, the vector control could be used as a negative control of two gRNAs.

As shown in Figure [4](#F4){ref-type="fig"}C, both 3-2 binary cassette and 3-M38-2 ternary cassette could significantly inhibit HBV replication, suggesting that the combination of two HBV-specific gRNAs exhibited a potent ability in suppressing HBV replication. It was consistent with our previous report in which gRNA5 and gRNA12 were corresponding to gRNA2 and gRNA3, respectively [@B24]. However, 3-2 binary cassette showed higher efficiency in suppressing HBV replication than that of 3-M38-2 ternary cassette, which might be due to the possibility of the longer RNA the lower transcription efficiency of U6 promoter. To test this possibility, the expression levels of gRNA2 in 3-2 binary cassette and 3-M38-2 ternary cassette was measured by qRT-PCR. The result revealed that the level of gRNA2 in 3-2 binary cassette was significantly higher than that of 3-M38-2 ternary cassette, which supported the above possibility (Figure [4](#F4){ref-type="fig"}D). Since the levels of mature miRNA (miR-HBV or mutant miR-HBV) and gRNA3 carrying flanking sequence of anti-HBV pri-miR-31 mimic were almost equal between 3-H38-2 and 3-M38-2 ternary cassettes, the transcription efficiencies of ternary cassette and the processing of pri-miRNA were similar between these two ternary cassettes (Figures [4](#F4){ref-type="fig"}E and [4](#F4){ref-type="fig"}F). While, the efficiency of 3-H38-2 ternary cassette in suppressing HBV replication was significantly higher than that of 3-M38-2 ternary cassette (Figure [4](#F4){ref-type="fig"}C). The above results suggested that miR-HBV and two HBV-specific gRNAs in gRNA-miR-HBV-gRNA ternary cassette can get a synergistic effect in suppressing HBV replication.

The gRNA-miR-HBV-gRNA ternary cassette can efficiently suppress the replication of multi-genotypes HBV *in vitro*
-----------------------------------------------------------------------------------------------------------------

To further show the efficiency of gRNA-miR-HBV-gRNA ternary cassette in suppressing the replication of multi-genotypes HBV, another ternary cassette composed by gRNA4, gRNA1 and an anti-HBV pri-miR-31 mimic carrying 38 bp flanking sequences was constructed, which was named as 4-H38-1 ternary cassette. As shown by a dual luciferase assay, 4-H38-1 could also efficiently produce miR-HBV ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S1). Since the target sequences of gRNAs 1-4 and miR-HBV were conserved in HBV genome of genotypes A-D, the consistent effect in suppressing the replication of multiple-genotypes HBV should be observed. The inhibitory effects of the individual gRNAs 1-4 in HBV replication have been confirmed in our previous study [@B24]. Consistently, both 3-H38-2 and 4-H38-1 ternary cassettes could significantly suppress the HBsAg, HBeAg and HBcAg levels of genotypes A to C HBV (Figure [5](#F5){ref-type="fig"}A-[5](#F5){ref-type="fig"}C). No significant effect of either gRNAs 1-4 or miR-HBV on cell proliferation was observed using an MTT assay, which suggested that miR-HBV and each gRNA were free of cytotoxicity ([Supplementary Figure](#SM1){ref-type="supplementary-material"} S2).

The gRNA-miR-HBV-gRNA ternary cassette can efficiently destroy HBV genome
-------------------------------------------------------------------------

To confirm the HBV-specific gRNAs-mediated suppression of HBV replication was through genome cleavage, the expression plasmids of 1.2×HBV and 3-2 binary, 3-M38-2 or 3-H38-2 ternary cassette were co-transfected into HuH7 cells, and the HBV DNA genome region covering the cleavage sites of gRNA2 and gRNA3 was amplified by PCR. Once two gRNAs mediated the double-strand break (DSB) of target DNA, the fragment between the cleavage sites would be removed, and a smaller PCR product would be detected. Consistent with our previous report [@B24], the smaller fragment was detected, especially for 3-2 binary cassette which cleft most HBV genome, indicating that the cleavage efficiency was extremely high (Figure [6](#F6){ref-type="fig"}A). Similarly to gRNA2 and gRNA3, gRNA1 and gRNA4 could also efficiently destroy HBV genome (Figure [6](#F6){ref-type="fig"}B). Furthermore, the Cas9/gRNA-mediated destruction of HBV genome was demonstrated by Southern Blot analyses ([Supplementary Figures](#SM1){ref-type="supplementary-material"} S2A and S2B). To confirm the cleavage specificity of two HBV-specific gRNAs, the smaller fragments of PCR products were sequenced directly. The results revealed that most rejoining sites were the gRNA-cleavage sites of two HBV-specific gRNAs (Figure [6](#F6){ref-type="fig"}C and [6](#F6){ref-type="fig"}D).

Since HBV-specific gRNA could destroy HBV DNA, theoretically, it could also destroy HBV cccDNA. To confirm this, the expression plasmid containing 3-2 binary cassette or 3-H38-2 ternary cassette was transfected into HepAD38 cells in which the HBV of genotype D was produced under the control of tet-off system [@B39]. Firstly, we demonstrated that 3-2 binary or 3-H38-2 ternary cassette in HepAD38 cells could also significantly reduce the HBsAg levels either in the cell culture supernatant or in cells, even the transfection efficiency was low (Figure [7](#F7){ref-type="fig"}A and [7](#F7){ref-type="fig"}B). Consistently, in the case of low transfection efficiency, 3-H38-2 ternary cassette could also significantly reduce the HBsAg levels in the culture supernatant of HepG2-NTCP-tet cells infected with HBV (Figure [7](#F7){ref-type="fig"}C). To overcome the interference of low transfection efficiency, the enhanced green fluorescence protein (EGFP) positive HepAD38 cells were selected by Flow Cytometry to enrich the successfully transfected cells which could express Cas9, EGFP and 3-2 binary or 3-H38-2 ternary cassette together. Since cccDNA reservoirs are the cause of chronic HBV infection, the level of cccDNA in the EGFP positive HepAD38 cells was measured. To make sure the quantitative measurement of the HBV cccDNA was reliable, KCl precipitation, plasmid-safe ATP-dependent DNase (PSAD) digestion and rolling circle amplification were employed, followed by the quantitative PCR with cccDNA specific primers (sense primer covers the cleavage site of gRNA3) that target the gap region of HBV genome. As expected, both 3-2 binary and 3-H38-2 ternary cassette could significantly decrease cccDNA level in HepAD38 cells (Figure [7](#F7){ref-type="fig"}D). Besides, HBV cccDNA could also be destroyed by both 3-2 binary and 3-H38-2 ternary cassette (Figure [7](#F7){ref-type="fig"}E). Intriguingly, the efficiency of 3-H38-2 ternary cassette on cccDNA destruction was significantly higher than that of 3-2 binary cassette, which was opposite to their effects on HBV DNA destruction (Figure [6](#F6){ref-type="fig"}A and Figure [7](#F7){ref-type="fig"}D). For this phenomenon, an explanation was that except for the direct cccDNA cleavage mediated by two gRNAs, miR-HBV might indirectly increase the percentage of destroyed cccDNA through suppressing HBV replication and subsequently inhibiting the supplement of cccDNA pool. To confirm this postulation, we used lamivudine (3TC) to treat HepAD38 cells transfected with the expression plasmid of 3-2 binary cassette and inhibit the supplement of cccDNA pool through suppressing HBV replication. Firstly, the synergistic effect of HBV-specific gRNA and 3TC was found in suppressing HBV replication (Figure [7](#F7){ref-type="fig"}F). Next, the gRNA-mediated cccDNA destruction was confirmed to be enhanced by 3TC treatment (Figure [7](#F7){ref-type="fig"}G), which supported the above hypothesis that miR-HBV might indirectly increase the proportion of destroyed cccDNA through inhibiting the supplement of cccDNA pool.

The gRNA-miR-HBV-gRNA ternary cassette can efficiently suppress HBV replication *in vivo*
-----------------------------------------------------------------------------------------

To further demonstrate the antiviral advantage of gRNA-miRNA-gRNA ternary cassette, hydrodynamic injection of the expression plasmids of 1.2×HBV and 3-2 binary or 3-H38-2 ternary cassette was conducted in C57BL/6 mice (5-7 weeks old). The HBsAg levels in serum were detected at 5 and 7 days post-injection. Intriguingly, 3-2 binary, 3-M38-2 and 3-H38-2 ternary cassettes could efficiently reduce the levels of HBsAg. The 3-H38-2 ternary cassette showed higher efficiency in inhibiting HBV replication, in which the HBsAg levels were below the lower limit of detection (Figure [8](#F8){ref-type="fig"}A). Furthermore, two mice of each group were sacrificed under anesthesia at 7 days post injection. The HBV DNA in the liver tissue was extracted and amplified by PCR. As expected, HBV-specific gRNA could also efficiently destroy HBV genome *in vivo*, and the cleavage efficiency was so high that most HBV genome was cleft (Figure [8](#F8){ref-type="fig"}B). Besides, the level of HBcAg in the liver tissue was measured by Western Blot and Immunohistochemistry assay (IHC) at 7 days post injection. The results of Western Blot analyses revealed that the levels of HBcAg were significantly reduced to the level that were undetectable with our relatively low-sensitive Western Blot analyses in the 3-2, 3-M38-2 and 3-H38-2 injected mice (Figure [8](#F8){ref-type="fig"}C). Consistently, compared to vector control group, the number of HBcAg-positive hepatocytes decreased significantly in the 3-2, 3-M38-2 and 3-H38-2 injected mice, even no HBcAg-positive hepatocyte was found in the 3-H38-2 injected mice (Figure [8](#F8){ref-type="fig"}D).

Discussion
==========

Clinically, the nucleos(t)ide analogues (NAs) and pegylated-interferon-α (PEG-IFN-α) are two kinds of antiviral agents commonly used to treat CHB. NAs block HBV replication mainly through inhibiting the reverse transcription of HBV pre-genome RNA, which have little or no direct effect on cccDNA. Since cccDNA is noticeably stable and declines slowly under NAs therapy, the recurrence of hepatitis B often occurs after the cessation of NAs treatment [@B4], [@B5], [@B40]. Although IFN-α can inhibit HBV replication through degradation of cccDNA, its efficiency is limited due to systemic side effect [@B6], [@B41]. Therefore, clinical cure of CHB is still an unresolved problem and a long-term treatment of CHB is required, which is expensive and may lead to concomitant resistant [@B40]. It is an urgent necessary to develop new strategies of clearing the persistent HBV cccDNA in hepatocytes.

In this report, a combined approach of CRISPR/Cas9 system and RNAi was developed. The HBV-specific gRNAs and miR-HBV were designed based on the conserved sequences among HBV genome of genotypes A-D which are the most predominant genotypes in the world [@B42]. Naturally, pri-miRNAs are transcribed from miRNA genes by RNA polymerase (Pol) II, and subsequently processed by nuclear RNaseIII enzyme Drosha together with DGCR8 to form pre-miRNAs in the nucleus, pre-miRNAs are ultimately processed by Dicer in the cytoplasm to form the resulting 19-24 nucleotides mature miRNAs [@B43]. Pri-miRNA mimic is the analogue of nascent miRNA, and can get silencing of the target gene by simulating natural miRNA processing [@B31], [@B32], [@B44]. To take advantage of this feature, we inserted an anti-HBV pri-miR-31 mimic between two HBV-specific gRNAs to construct a gRNA-miR-HBV-gRNA ternary cassette. Although a modest flanking sequence (≥8 bp) beyond the 5\' end of a pre-miRNA is required for the recognition of Drosha/DGCR8 and subsequent cleavage of pri-miRNA [@B45], the flanking sequence of anti-HBV pri-miR-31 mimic may interfere with the activity of gRNA. Therefore, to get the maximal anti-HBV efficiency, a series of anti-HBV pri-miR-31 mimics carrying different lengths of flanking sequences were designed based on the pri-miR-31/5 sequence which was successfully applied for inhibiting HBV replication [@B32]. As expected, HBV-specific gRNAs and miR-HBV could be efficiently expressed and separated in gRNA-miR-HBV-gRNA ternary cassette. Although the production of the artificially designed miR-HBV was the same with miRNA, its activity should be similar with the short interference RNA (siRNA), because its sequence was completely matched with the target sequence. Since the longer flanking sequence of anti-HBV pri-miR-31 mimic the stronger ability in suppressing luciferase activity in which miR-HBV-target sequence (HBV 1575-1595) was located at 3\' UTR region of luciferase gene, the expression level of mature miR-HBV should be increased with the increase in length of flanking sequence. Whereas, a 38 bp flanking sequence of anti-HBV pri-miR-31 mimic in the gRNA-miR-HBV-gRNA ternary cassette was the optimal length in suppressing HBV replication, but not a 51 bp flanking sequence, which suggested that the 5\' end and 3\' end extension of two resulting gRNAs might affect their cleavage efficiencies.

Next, the *in vitro* and *in vivo* experiments were conducted to evaluate the antiviral effect of gRNA-miR-HBV-gRNA ternary cassette, and showed that this ternary cassette could efficiently suppress the replication of genotype A to D HBV, including the levels of HBsAg, HBeAg and HBcAg. Further, PCR, Southern Blot or direct sequencing confirmed that two HBV-specific gRNAs expressed from gRNA-miR-HBV-gRNA ternary cassette could efficiently and specifically destroy HBV genome *in vitro* and in *vivo*, suggesting that the anti-HBV effect of CRISPR/Cas9 was due to the cleavage of HBV genome. However, the cleavage efficiency of gRNA-miR-HBV-gRNA ternary cassette was lower than that of gRNA-gRNA binary cassette. For this phenomenon, one reason was that the transcription efficiency of U6 promoter for the long gRNA-miR-HBV-gRNA ternary cassette (about 340 bp) was lower than that of gRNA-gRNA binary cassette (about 100 bp), another reason might be that the flanking sequences of anti-HBV pri-miR-31 mimic interfered with the activity of gRNA. When targeted by a single gRNA, the DNA cleft by Cas9 usually underwent the non-homologus end joining (NHEJ) repair, even for the HBV genome, which introduces the indel mutation and inhibits HBV replication [@B46], [@B47]. Since dual gRNAs can remove the DNA fragment between two gRNAs, the damage in HBV genome should be greater than that of single gRNA. Interestingly, the indel mutation was not found in the sequencing map of the smaller PCR product. It was suggested that the DNA fragment between two gRNAs was precisely removed, which was consistent with our and other\'s previous reports [@B24], [@B27]. It was indicated that two cleavage sites might rapidly ligate without forming indel mutation when a fragment of HBV genome was removed by two gRNAs.

Intriguingly, we found that the gRNA-miR-HBV-gRNA ternary cassette could get higher efficiency in suppressing HBV replication than that of the gRNA-gRNA binary cassette, suggesting a synergistic effect of CRISPR/Cas9 system and RNAi approach. It has been reported that HBV cccDNA can be cleft by CRISPR/Cas9 system in HuH7 and HepG2 cells after transfection [@B46]-[@B49]. Consistently, we found that gRNA-miR-HBV-gRNA ternary cassette could also efficiently destroy HBV cccDNA in HepAD38 cells, and the efficiency was higher than that of gRNA-gRNA binary cassette, which was different from the observation in HBV genome of 1.2×HBV expression plasmid. For this phenomenon, we postulated that miR-HBV might additionally inhibit the supplement of cccDNA pool in HepAD38 cells by suppressing HBV replication, and thus indirectly promoted the CRISPR/Cas9 system-mediated destruction of cccDNA. To confirm the above postulation, lamivudine (3TC) treatment was used to suppress HBV replication and subsequently inhibit the supplement of cccDNA pool. Consistently, 3TC treatment indeed could promote the gRNA-gRNA binary cassette-mediated destruction of cccDNA. These results exhibited the superiority of gRNA-miR-HBV-gRNA ternary cassette in suppressing HBV replication and destroying HBV cccDNA.

As we know, the off-target effect of CRISPR/Cas9 system is a common problem and poses a major challenge for its clinical application. Since the possibility of non-specific effects could not be completely addressed using wild-type SpCas9, and it is likely to be higher when the number of gRNAs introduced into cell is increased. Fortunately, some SpCas9 variants can reduce off-target effects to undetectable level [@B50], [@B51]. Therefore, it is possible for the ultimate therapeutic utility of this technology. More excitingly, Staphylococcus aureus Cas9 (SaCas9) and its gRNA expression cassette can be packaged into a single adeno-associated virus (AAV) vector, which make a step further in the clinical application of CRISPR/Cas9 system [@B52]. Therefore, the gRNA-miR-HBV-gRNA ternary cassette can be inserted into the SaCas9-AAV expression vector to promote the clinical application of the gRNA-miRNA-gRNA ternary cassette. Besides, based on the gRNA-miRNA-gRNA ternary cassette, we can get the gRNA-miRNA-gRNA-miRNA-gRNA......multiplex gRNAs and miRNAs expression cassette for multiplex genes editing.

In conclusion, our results proved that gRNA-miR-HBV-gRNA ternary cassette could efficiently suppress the replication of multi-genotypes HBV through RNAi and destroying HBV genome, which showed the synergistic or additional effect of CRISPR/Cas9 system and RNAi approach. The development of gRNA-miRNA-gRNA ternary cassette should make them broadly useful in research and therapeutic applications for genome editing, particularly for antiviral therapy.
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![**The schematic diagram of the HBV-specific gRNA-miR-HBV-gRNA cassette.**(**A**) Schematic illustration of gRNA-miR-HBV-gRNA cassette. (**B**) The locations of gRNA and miR-HBV target sites in HBV genome. nt: nucleotide. (**C**) The sequences of pri-miR31 and anti-HBV pri-miR-31 mimics with different lengths (base pairs, bp) of flanking sequences.](thnov07p3090g001){#F1}

![**Detection on the expression of functional HBV-specific gRNAs and miR-HBV from gRNA3-miR-HBV-gRNA2 cassette.** (**A**) The sequences of 3-H38-2 and 3-H51-2 ternary cassettes. The triangle indicates the cleavage site of endogenous Drosha/DGCR8. (**B**) The expression plasmid containing 3-H38-2 or 3-H51-2 ternary cassette was transfected into HuH7 cells. Cellular small RNA (\<200 bp) was harvested at 48 hours after transfection, then polyA tailing, anchoring random sequence through reverse transcription and PCR amplification were performed to detect the expression of separated HBV-specific gRNA3 and miR-HBV. Clone-based sequencing analyses of the above PCR products were conducted to confirm the expression of mature miR-HBV (**C**) and HBV-specific gRNA3 with flanking sequence (**D**) of anti-HBV pri-miR-31 mimics.](thnov07p3090g002){#F2}

![**The effect of anti-HBV pri-miR-31-mimic flanking sequence in ternary cassette.** (**A**) A dual-luciferase assay was conducted to detect the production of functional miR-HBV from gRNA3-miR-HBV-gRNA2 cassettes with different lengths of anti-HBV pri-miR-31 mimic in HuH7 cells co-transfected with pGL3-HBV (1575-1604) or pGL3-control, PRL-TK and each of the plasmids containing gRNA3-miR-HBV-gRNA2 cassettes with different length of anti-HBV pri-miR-31 mimics. The vectors pGL3-control and PRL-TK were used as negative control and internal control, respectively. Data was shown as mean±SD of 4 independent experiments. (**B**) A polyA tailing reaction and a quantitative reverse transcription-PCR (qRT-PCR) were conducted to detect the production of mature miR-HBV in HuH7 cells transfected with the plasmids containing gRNA3-miR-HBV-gRNA2 cassettes with different length of anti-HBV pri-miR-31 mimics. (**C**) Schematic illustration of gRNA-gRNA binary cassette. (**D**) The expression plasmid of 1.2×HBV was co-transfected with the expression plasmid containing 3-2 binary cassette or gRNA3-miR-HBV-gRNA2 ternary cassette with different length of anti-HBV pri-miR-31 mimic flanking sequence in HuH7 cells at the ratio of 3:1 and 1:3. HBsAg levels in the cell culture supernatant were measured using a time-resolved fluoroimmunoassay at 72 hours after transfection. Data was shown as mean±SD of 5 independent experiments. (\* indicated *P*\<0.05, Mann-Whitney U test). PX458 plasmid was used as a vector control. 5S rRNA was used as the internal control.](thnov07p3090g003){#F3}

![**The function of miR-HBV in gRNA-miR-HBV-gRNA ternary cassettes.**(**A**) A dual-luciferase assay was conducted to analyze the effect of 3-M38-2 ternary cassette in the target sequence of miR-HBV. The 3-M38-2 ternary cassette was used as a positive control. Data was shown as mean±SD of 5 independent experiments. (**B**) The expression plasmids of 1.2×HBV (genotype C) and miR-HBV or mutant miR-HBV (miR-HBVm) were co-transfected into HuH7 cells. The HBsAg levels in the cell and culture supernatant of HuH7 cells were measured using a time-resolved fluoroimmunoassay at 48 hours after transfection. Data was shown as mean±SD of 4 independent experiments. (**C**) The expression plasmids of 1.2×HBV and 3-2 binary cassette, 3-M38-3 or 3-H38-2 ternary cassette were co-transfected into HuH7 cells. The levels of HBsAg and HBeAg in the culture supernatant were measured using a time-resolved fluoroimmunoassay at 72 hours after transfection. Data was shown as mean±SD of 5 independent experiments. (D) The level of gRNA2 in the HuH7 cells transfected with the expression plasmid of vector control, 3-2 binary or 3-H38-2 ternary cassette was detected by qRT-PCR (SYBR Green). The level of (E) gRNA3 carrying flanking sequence of anti-HBV pri-miR-31 mimic and (F) mature miRNA (miR-HBV or mutant miR-HBV) in the HuH7 cells transfected with the expression plasmid of vector control, 3-2 binary or 3-H38-2 ternary cassette was detected by qRT-PCR (SYBR Green). Data was shown as mean±SD of 4 independent experiments. (\*\* indicated *P*\<0.01, \*\*\*indicated *P*\<0.001, Mann-Whitney U test). PX458 plasmid was used as a vector control.](thnov07p3090g004){#F4}

![**The efficiency of gRNA-miR-HBV-gRNA ternary cassettes in suppressing HBV replication.** The expression plasmids of each genotype (A, B or C) HBV and 3-H38-2 or 4-H38-1 cassette were co-transfected into HuH7 cells, and the levels of HBsAg (**A**) and HBeAg (**B**) in the cell culture supernatant or cells were measured using a time-resolved fluoroimmunoassay at 72 hours after transfection. Data was shown as mean±SD of 5 independent experiments. (**C**) The level of HBcAg in the HuH7 cells co-transfected with the expression plasmids of each genotype (A, B or C) HBV and 3-H38-2 or 4-H38-1 cassette were measured by Western Blot. The right figures were the statistical graphs of Western Blot, which was analyzed by Image J software (NIH, Bethesda, USA) at least in triplicate. HBc: HBcAg. PX458 plasmid was used as a vector control. (\*\* indicated P\<0.01, \*\*\*indicated P\<0.001, Mann-Whitney U test).](thnov07p3090g005){#F5}

![**Detection on the HBV-specific gRNAs-mediated destruction of HBV genome.** (**A**) The expression plasmids of 1.2×HBV and 3-2 binary, 3-M38-2, 3-H38-2 or 4-H38-1 (**B**) ternary cassette were co-transfected into HuH7 cells. Cellular DNA was extracted at 72 hours after transfection, and PCR amplifications were performed using the primers beyond the cleavage sites of two gRNAs. (**C**) Sequencing analysis of the smaller fragment cleft by gRNA2 and 3. (**D**) Sequencing analysis of the smaller fragment cleft by gRNA1 and 4. PX458 plasmid was used as a vector control.](thnov07p3090g006){#F6}

![**Detection on the HBV-specific gRNAs-mediated destruction of HBV cccDNA.** (**A**) HepAD38 cells were seeded into 10 cm dish. The expression plasmid of gRNA3-RNA2 binary or gRNA-miRNA-gRNA ternary cassette was co-transfected into HepAD38 cells. Transfection efficiency of HepAD38 cells was evaluated by observing the enhanced green fluorescent protein (EGFP) expressing cells under immunofluorescence microscopy. (**B**) HBsAg and HBeAg levels in the cell culture supernatant of HepAD38 cells were measured using a time-resolved fluoroimmunoassay. Data was shown as mean±SD of 6 independent experiments. (**C**) HBsAg levels in the cell culture supernatant of HepG2-NTCP-tet cells were measured using a time-resolved fluoroimmunoassay. Data was shown as mean±SD of 5 independent experiments. (**D**) HBV cccDNA levels in EGFP positive HepAD38 cells selected by Flow cytometry were measured using a KCl precipitation, plasmid-safe ATP-dependent DNase (PSAD) digestion, rolling circle amplification and quantitative PCR (SYBR green) combined method. Data was shown as mean±SD of 4 independent experiments. (**E**) PCR amplification of cccDNA was performed using the primers beyond the cleavage sites of two gRNAs following above rolling circle amplification. HepAD38 cells were transfected with 3-2 binary cassette expression plasmid, and then treated with or without lamivudine (3TC). The HBV DNA levels (**F**) in HepAD38 cells were detected by quantitative PCR, and HBV cccDNA levels (**G**) in EGFP positive HepAD38 cells selected by Flow cytometry were measured as above. Data was shown as mean±SD of 4 independent experiments. (\* indicated *P*\<0.05, \*\* indicated *P*\<0.01, Mann-Whitney U test). PX458 plasmid was used as a vector control.](thnov07p3090g007){#F7}

![**The efficiency of the gRNA-miR-HBV-gRNA ternary cassettes in suppressing HBV replication *in vivo*.** (**A**) Hydrodynamic injection of the 1.2×HBV (8µg) and gRNA3-RNA2 binary or gRNA-miRNA-gRNA ternary cassette expression plasmids (24µg) in C57BL/6 mice. The HBsAg levels (lgIU/mL) in sera were detected at 5 and 7 days post-injection (DPI) \[\*\*\* indicated *P*\<0.001, Kruskal-Wallis H (K) test\]. (**B**) Liver tissue DNA was extracted at 7 days post-injection, and PCR amplifications were performed using the primers beyond the cleavage sites of each gRNAs. 1: liver tissue from 1\# mice. 2: liver tissue from 2\# mice. (**C**) The levels of HBcAg in the liver tissues of mice at 7 days post-injection were detected by Western Blot. The right figures were the statistical graphs of Western Blot, which was analyzed by Image J software (NIH, Bethesda, USA) at least in triplicate. HBc: HBcAg. (\*\* indicated *P*\<0.01, \*\*\*indicated *P*\<0.001, Mann-Whitney U test). HBcAg: HBc. (**D**) Representative micrographs showing the levels of HBcAg in the liver tissues measured by IHC at 7 days post-injection. The red triangle indicates the HBcAg positive hepatocytes.](thnov07p3090g008){#F8}
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